TelyRx Holdings (TELYF) appointed Benjamin Atkins to its Board of Directors effective November 5, 2026, succeeding Andrew Brandt.
Brandt is stepping down to focus on other commitments. Atkins is a founder and major shareholder of TelyRx with more than 25 years of experience in healthcare and real estate. He currently serves as Chairman of the Board of Waterfall Bank.
TelyRx (TELYF) reported third-quarter 2026 revenue of $23.1 million, up 88% from the same period last year.
Gross margin rose to 60% from 56%, while operating loss widened to $2.744 million from $947,000. Net loss increased to $2.829 million from $1.058 million. The adjusted EBITDA loss, a non-IFRS earnings measure, widened to $1.277 million from $351,000, although the company said it narrowed by more than half sequentially.
Recurring customers contributed $17.4 million of revenue and new customers $5.7 million. Cash and cash equivalents were $8.477 million at September 30, with another $10.2 million restricted as credit-facility collateral. Nine-month free cash outflow reached $9.362 million, versus $1.449 million a year earlier. TelyRx plans an expansion that it expects to more than triple Clearwater capacity and reported a 17% improvement in revenue per visitor following its brand and website launch.
TelyRx Holdings (TELYF) will host its third-quarter 2026 financial results conference call and webcast on November 6, 2026. The call starts at 8:30 a.m. Eastern Time. The company expects to release results for the period ended September 30, 2026, after market close on November 5, 2026.
TelyRx Holdings (TELYF) is expanding its menopause offerings through a partnership with SISTERLY to offer the women's health brand's supplement.
The partnership launches in October 2026. TelyRx will become SISTERLY's first U.S. pharmacy partner to offer The Elevator, a daily multivitamin containing 23 nutrients in a powder sachet. The supplement will sit alongside TelyRx's existing prescription menopause treatments, broadening the options available for women navigating perimenopause and menopause.
TelyRx (TSX: TELY, OTCQX: TELYF) reported second quarter 2026 revenue of $22.7 million, up from $9.3 million in Q2 2025, a 143% increase. Recurring revenue reached $15.6 million, about 70% of total revenue, with a 23% sequential increase and a 7.7% compounded monthly growth rate.
Gross profit rose to $13.0 million with a 57% margin, compared with $5.1 million and a 54% margin a year earlier. Net loss from operations widened to $5.5 million, mainly due to $1.8 million of non-cash stock-based compensation, higher advertising and marketing, and expanded operating expenses. Adjusted EBITDA loss increased to $3.2 million from $0.9 million. Cash and cash equivalents were $21.7 million as of June 30, 2026, versus $2.7 million a year earlier. For the six months ended June 30, 2026, Free Cash Flow was a negative $6.4 million, compared with a negative $1.0 million in 2025.
TelyRx (TSX: TELY, OTCQX: TELYF) launched a new brand platform and digital pharmacy experience built from two years of patient feedback. The updated TelyRx.com enables online ordering of routine medications with improved treatment discovery, transparent pricing, delivery tracking and reduced complexity.
According to TelyRx, its offering has expanded to more than 500 medications, up from about 400 at the start of the year. The company reports having filled over one million prescriptions nationwide and highlights more than 3,600 five-star Trustpilot reviews and a growing base of repeat customers.
TelyRx (TSX: TELY, OTCQX: TELYF) will host a conference call and webcast to discuss its second quarter 2026 financial results on Monday, August 10, 2026 at 8:30 a.m. ET. The company expects to release the results by news release at approximately 7:00 a.m. ET the same day.
Investors can join via telephone using the provided North American and international dial-in numbers or access a live webcast through the specified online link, with participants asked to connect about 15 minutes early.
TelyRx (TSX: TELY, OTCQX: TELYF) announced a major expansion of its Clearwater, Florida headquarters and pharmacy operations after surpassing one million prescriptions filled and reporting first-quarter revenue growth of 180% year-over-year. The move more than triples the company’s physical footprint to support rising demand for its digital healthcare and online pharmacy platform.
TelyRx’s integrated platform links patients with licensed providers and pharmacy services for FDA-approved medications used in routine care. The company is also recruiting across pharmacy, clinical and fulfillment roles to preserve service levels and support scaling as adoption of virtual care solutions increases.
TelyRx Holdings (TSX: TELY, OTCQX: TELYF) announced that its subordinate voting shares are now DTC eligible for electronic clearing and settlement in the U.S. through the Depository Trust Company. According to TelyRx, this is expected to simplify trading, improve settlement efficiency, and enhance liquidity and accessibility for U.S. investors by enabling trading across a wider network of brokerage firms.
TelyRx (OTCQX:TELYF) reported voting results from its June 15, 2026 Annual Meeting of Shareholders. All nominated directors were elected and the additional resolution submitted to shareholders was approved.
Votes for nominees ranged from 8,788,172 (69.42%) for Michael Handler to 12,659,534 (100%) for Andrew Brandt.